Cantharidin-Based Drug-Device Combination Likely Safe, Effec
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
VP-102, a proprietary drug-device combination containing 0.7% cantharidin, was safe and effective in two phase 3 trials in children with molluscum contagiosum (MC).

Molluscum contagiosum is one of the most common viral skin infections in children and one of the five most prevalent skin diseases worldwide. The positive results from Verrica's Phase 3 CAMP (Cantharidin Application in Molluscum Patients) trials demonstrate that VP-102, which is delivered via a single-use applicator that allows for precise topical dosing and targeted administration, may be a viable treatment option for pediatric and adult patients with molluscum.

In two phase-three trials spanning 31 centers across the US, 527 participants (mean age around 7; about half boys) were randomized (3:2) to apply topical VP-102 or vehicle to all treatable lesions every 21 days until complete lesion clearance or up to four treatment. The main efficacy outcome was the proportion of VP-102-treated participants achieving complete clearance of all MC lesions (baseline and new) compared with those who received vehicle at the end-of-study visit on day 84. As reported in, treatment with VP-102 was more efficacious than vehicle on day 84 in the percentage of participants with complete clearance of MC lesions for CAMP-1 (46.3% vs. 17.9%) and CAMP-2 (54% vs. 13.4%).

Adverse events occurred in 99% (CAMP-1) and 95% (CAMP-2) of VP-102-treated participants and 73% (CAMP-1) and 66%(CAMP-2) of those who received vehicle. The most common adverse events were application site vesicles, pain, pruritus, erythema, and scab. Most events were mild or moderate.

Adherence was high: 93.2% of participants who received VP-102 and 95.4% of those who received vehicle completed the trials. These trials provide robust efficacy and safety data that support the use of VP-102 for the treatment of MC in participants aged 2 years and older.

Enter VP-102, taking something that patients are familiar with and often prefer, given the painless nature of application - especially when considering pediatric patients - and offering a new and potentially easier way to deliver it.